LIMINATUS PHARMA, INC.
Market Cap
$5.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Go deeper on LIMINATUS PHARMA, INC. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on LIMN — live, with citations.
Key Financialsas of March 31, 2026
Quarterly Burn
$2.0M
Free Cash Flow
-$2.0M
Total Liabilities
$2.9M
Shareholders Equity
-$133K
Current Ratio
0.96
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$182K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 677,518 | $116K |
| geode capital management, llc | 117,783 | $20K |
| vanguard capital management llc | 100,880 | $17K |
| jane street group, llc | 71,318 | $12K |
| vanguard fiduciary trust co | 22,984 | $4K |
| two sigma securities, llc | 22,039 | $4K |
| state street corp | 19,000 | $3K |
| blackrock, inc. | 13,254 | $2K |
| tower research capital llc (trc) | 7,567 | $1K |
| citigroup inc | 6,769 | $1K |
Showing top 10 of 11 institutional holders of LIMINATUS PHARMA, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
Who is the CEO of LIMINATUS PHARMA, INC.?
Mr. Chris Kim J.D., L.L.M. is the chief executive officer of LIMINATUS PHARMA, INC. (LIMN).
Where is LIMINATUS PHARMA, INC. headquartered?
LIMINATUS PHARMA, INC. (LIMN) is headquartered in Cerritos, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on LIMINATUS PHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.